Announcements Trials

Browse Landscape

Status

No longer available 1

Sponsor Class

Study Type

Interventional 217 Observational 18 Expanded_access 1

Sponsor

Cancer Type

Conditions

EGFR T790M Mutation Positive NSCLC 1

Interventions

Afatinib 3 ceritinib 2 Gefitinib 2 zipalertinib 1 zenocutuzumab 1 ulixertinib 1 trilaciclib 1 telisotuzumab vedotin 1 tazemetostat 1 taletrectinib 1 sotorasib 1 selpercatinib 1 rovalpituzumab tesirine 1 rociletinib 1 pralsetinib 1 pegilodecakin 1 patritumab deruxtecan 1 osimertinib 1 mobocertinib 1 lorlatinib 1 lazertinib 1 epigallocatechin gallate 1 ensartinib 1 dabrafenib 1 cemiplimab 1 capmatinib 1 brigatinib 1 belagenpumatucel L 1 balstilimab 1 amivantamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × osimertinib × Thoracic × Clear all

NCT02451852 2016-07-14

AZD9291 US Expanded Access Program

AstraZeneca

No longer available

EGFR T790M Mutation Positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡